Education > XRAY > Search Results

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 43

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Women support delayed removal of ovaries

Most relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.

Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study.  This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)

Read More
Women support delayed removal of ovaries

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More
Coping with chemotherapy-induced hair loss

Relevance: Medium-High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Most relevant for: Women with advanced-stage ovarian cancer

Treatment with veliparib may benefit women with advanced ovarian cancer. A recent clinical trial shows that this new PARP inhibitor may delay progression of cancer when combined with chemotherapy and when continued alone as a maintenance therapy. (8/18/20)

Read More
New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science
View Related Clinical Trials

Update : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)

The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)

Read More
FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

Most relevant for: People with advanced ovarian cancer who have had a complete or partial response to chemotherapy

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)

Read More
New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

Topic : COVID-19 and Cancer

Most relevant for: People in treatment for cancer, or people scheduled for surgery

The current COVID-19 pandemic has led to many changes in our communities. In this XRAY review we focus on the intersection between COVID-19 and cancer: who may be immunosuppressed, coping with changes in surveillance or treatment, and evaluating and dealing with media. (4/13/20)

Este artículo está disponible en español.

Read More
COVID-19 and Cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Cancer risk associated with inherited mutations in Lynch syndrome genes

Most relevant for: People with Lynch syndrome mutations

Lynch syndrome is the most common inherited cause of cancer affecting about 1 in 300 people. People with Lynch syndrome have an increased risk of colorectal endometrial and other cancers. A large study followed people with mutations in the Lynch syndrome genes MLH1, MSH2, MSH6 and PMS2 to determine the risk of other types of cancer. (2/21/20)

Read More
Cancer risk associated with inherited mutations in Lynch syndrome genes

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Second surgery may not benefit women with recurrent ovarian cancer

Most relevant for: Women with recurrent ovarian cancer

Many women who have recurrent ovarian cancer have a second surgery. A new study suggests that women with platinum sensitive cancers who get chemotherapy alone may do as well as or better than women who have surgery followed by chemotherapy. (1/21/20)

Read More
Second surgery may not benefit women with recurrent ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Most relevant for: Women newly-diagnosed with ovarian cancer

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Read More
Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Supportive care can improve quality of life for people with metastatic breast cancer

Most relevant for: People diagnosed with metastatic breast cancer

Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)

Read More
Supportive care can improve quality of life for people with metastatic breast cancer